What topical agents are available for the treatment of cutaneous T-cell lymphoma (CTCL)?

Updated: Apr 20, 2020
  • Author: Lauren C Pinter-Brown, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Retinoids are vitamin A analogues involved in the modulation of cell growth, division, reproduction, and differentiation. [104] Their biologic effects result from alterations in gene expressions that are mediated through 2 major types of nuclear receptors, the retinoic acid receptor and the retinoic X receptor. Each receptor subtype likely controls the expression of unique and common genes. Subclass-specific retinoids are available.

Mechlorethamine topical (Valchlor) was approved in August 2013 for mycosis fungoides–type cutaneous T-cell lymphoma (MF-type CTCL). Approval was based on a trial in patients with refractory stage IA-IIA MF-type CTCL, in which 60% of patients treated with mechlorethamine had a confirmed response at 12 months, compared with 48% of those treated with a pharmacy-compounded mechlorethamine preparation. [105, 106, 107]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!